Aptuit, Inc. today announced that it has completed the acquisition of the Chemical and Pharmaceutical Development (CPD) business of Evotec, which integrates an active pharmaceutical ingredient (API) facility in Oxford, England and a well-established and recently-expanded parenteral (injectable vials) fill/finish facility in Glasgow, Scotland into Aptuit’s global network. The integration of these development and small scale manufacturing facilities in Europe completes a unique global API supply chain where small scale development takes place in the US and Europe with commercial scale undertaken in new state of the art facilities in India. Aptuit brings this service to its current client base of more than 750 pharmaceutical innovators.

“Over the past 18 months we’ve assembled by strategic acquisitions the core competencies that are key to reducing the time and cost burdens of drug development for our customers, and that also build on our commitment to operate an efficient, integrated global network. This particular acquisition is an important building block for Aptuit as we move toward completing that network,” said Michael A. Griffith, Chief Executive Officer and Founder of Aptuit. “As the overall life science industry evolves, we are continuously evaluating the ways in which the drug development process must change and improve, and executing forward-looking deals and partnerships that are beneficial to our customers now and for the life of their products.”